Combined MAPK Pathway and HDAC Inhibition Breaks Melanoma

Combined MAPK Pathway and HDAC Inhibition Breaks Melanoma

In this issue, Maertens and colleagues demonstrate that HDAC3 inhibition potentiates the effects of MAPK pathway inhibitors in melanoma, including difficult-to-treat - and -driven tumors, with expression serving as a biomarker for responsiveness to the BRAF/MEK/HDAC inhibitor combination. Mechanisti...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Cancer discovery 2019-04, Vol.9 (4), p.469-471
Hauptverfasser: Lombard, David B, Cierpicki, Tomasz, Grembecka, Jolanta
Format: Artikel
Sprache:eng
Schlagworte:
DNA Repair - drug effects
GTP Phosphohydrolases - genetics
Humans
Melanoma - genetics
Membrane Proteins - genetics
Protein Kinase Inhibitors
Proto-Oncogene Proteins B-raf - genetics
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 471
container_issue 4
container_start_page 469
container_title Cancer discovery
container_volume 9
creator Lombard, David B
Cierpicki, Tomasz
Grembecka, Jolanta
description In this issue, Maertens and colleagues demonstrate that HDAC3 inhibition potentiates the effects of MAPK pathway inhibitors in melanoma, including difficult-to-treat - and -driven tumors, with expression serving as a biomarker for responsiveness to the BRAF/MEK/HDAC inhibitor combination. Mechanistically, this triple cocktail suppresses expression of genes involved in DNA repair, leading to enhanced killing of melanoma cells. .
doi_str_mv 10.1158/2159-8290.CD-19-0069
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6446927</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2202196730</sourcerecordid><originalsourceid>FETCH-LOGICAL-c408t-8a0246d8595ca42d0bccc53944217756f085709e3eb9d49c153fa8a68078a3be3</originalsourceid><addsrcrecordid>eNpVkE1PwzAMhiMEYtPYP0CoRy4d-WySC9LogE1sYgc4R2maskLbjKYD7d_TaqMCX2z547X9AHCJ4AQhJm4wYjIUWMJJPAuRDCGM5AkY9unTPuZ0AMbev8PWqKQM8nMwIFCSCCM5BDJ2ZZJXNg1W0_VTsNbN5lvvA12lwXw2jYNFtcmTvMldFdzVVn_4YGULXblSX4CzTBfejo9-BF4f7l_iebh8flzE02VoKBRNKDTENEoFk8xoilOYGGMYkZRixDmLMigYh9ISm8iUSoMYybTQkYBcaJJYMgK3B93tLiltamzV1LpQ2zovdb1XTufqf6XKN-rNfamI0khi3gpcHwVq97mzvlFl7o0t2jes23mFMWxRRJzAtpUeWk3tvK9t1q9BUHXgVUdVdYRVPFNIqg58O3b198R-6Bcz-QFMc3y2</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2202196730</pqid></control><display><type>article</type><title>Combined MAPK Pathway and HDAC Inhibition Breaks Melanoma</title><source>MEDLINE</source><source>American Association for Cancer Research</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Lombard, David B ; Cierpicki, Tomasz ; Grembecka, Jolanta</creator><creatorcontrib>Lombard, David B ; Cierpicki, Tomasz ; Grembecka, Jolanta</creatorcontrib><description>In this issue, Maertens and colleagues demonstrate that HDAC3 inhibition potentiates the effects of MAPK pathway inhibitors in melanoma, including difficult-to-treat - and -driven tumors, with expression serving as a biomarker for responsiveness to the BRAF/MEK/HDAC inhibitor combination. Mechanistically, this triple cocktail suppresses expression of genes involved in DNA repair, leading to enhanced killing of melanoma cells. .</description><identifier>ISSN: 2159-8274</identifier><identifier>EISSN: 2159-8290</identifier><identifier>DOI: 10.1158/2159-8290.CD-19-0069</identifier><identifier>PMID: 30936219</identifier><language>eng</language><publisher>United States</publisher><subject>DNA Repair - drug effects ; GTP Phosphohydrolases - genetics ; Humans ; Melanoma - genetics ; Membrane Proteins - genetics ; Protein Kinase Inhibitors ; Proto-Oncogene Proteins B-raf - genetics</subject><ispartof>Cancer discovery, 2019-04, Vol.9 (4), p.469-471</ispartof><rights>2019 American Association for Cancer Research.</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c408t-8a0246d8595ca42d0bccc53944217756f085709e3eb9d49c153fa8a68078a3be3</citedby><cites>FETCH-LOGICAL-c408t-8a0246d8595ca42d0bccc53944217756f085709e3eb9d49c153fa8a68078a3be3</cites><orcidid>0000-0002-4292-0185</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,780,784,885,3356,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30936219$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lombard, David B</creatorcontrib><creatorcontrib>Cierpicki, Tomasz</creatorcontrib><creatorcontrib>Grembecka, Jolanta</creatorcontrib><title>Combined MAPK Pathway and HDAC Inhibition Breaks Melanoma</title><title>Cancer discovery</title><addtitle>Cancer Discov</addtitle><description>In this issue, Maertens and colleagues demonstrate that HDAC3 inhibition potentiates the effects of MAPK pathway inhibitors in melanoma, including difficult-to-treat - and -driven tumors, with expression serving as a biomarker for responsiveness to the BRAF/MEK/HDAC inhibitor combination. Mechanistically, this triple cocktail suppresses expression of genes involved in DNA repair, leading to enhanced killing of melanoma cells. .</description><subject>DNA Repair - drug effects</subject><subject>GTP Phosphohydrolases - genetics</subject><subject>Humans</subject><subject>Melanoma - genetics</subject><subject>Membrane Proteins - genetics</subject><subject>Protein Kinase Inhibitors</subject><subject>Proto-Oncogene Proteins B-raf - genetics</subject><issn>2159-8274</issn><issn>2159-8290</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpVkE1PwzAMhiMEYtPYP0CoRy4d-WySC9LogE1sYgc4R2maskLbjKYD7d_TaqMCX2z547X9AHCJ4AQhJm4wYjIUWMJJPAuRDCGM5AkY9unTPuZ0AMbev8PWqKQM8nMwIFCSCCM5BDJ2ZZJXNg1W0_VTsNbN5lvvA12lwXw2jYNFtcmTvMldFdzVVn_4YGULXblSX4CzTBfejo9-BF4f7l_iebh8flzE02VoKBRNKDTENEoFk8xoilOYGGMYkZRixDmLMigYh9ISm8iUSoMYybTQkYBcaJJYMgK3B93tLiltamzV1LpQ2zovdb1XTufqf6XKN-rNfamI0khi3gpcHwVq97mzvlFl7o0t2jes23mFMWxRRJzAtpUeWk3tvK9t1q9BUHXgVUdVdYRVPFNIqg58O3b198R-6Bcz-QFMc3y2</recordid><startdate>201904</startdate><enddate>201904</enddate><creator>Lombard, David B</creator><creator>Cierpicki, Tomasz</creator><creator>Grembecka, Jolanta</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-4292-0185</orcidid></search><sort><creationdate>201904</creationdate><title>Combined MAPK Pathway and HDAC Inhibition Breaks Melanoma</title><author>Lombard, David B ; Cierpicki, Tomasz ; Grembecka, Jolanta</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c408t-8a0246d8595ca42d0bccc53944217756f085709e3eb9d49c153fa8a68078a3be3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>DNA Repair - drug effects</topic><topic>GTP Phosphohydrolases - genetics</topic><topic>Humans</topic><topic>Melanoma - genetics</topic><topic>Membrane Proteins - genetics</topic><topic>Protein Kinase Inhibitors</topic><topic>Proto-Oncogene Proteins B-raf - genetics</topic><toplevel>online_resources</toplevel><creatorcontrib>Lombard, David B</creatorcontrib><creatorcontrib>Cierpicki, Tomasz</creatorcontrib><creatorcontrib>Grembecka, Jolanta</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Cancer discovery</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lombard, David B</au><au>Cierpicki, Tomasz</au><au>Grembecka, Jolanta</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Combined MAPK Pathway and HDAC Inhibition Breaks Melanoma</atitle><jtitle>Cancer discovery</jtitle><addtitle>Cancer Discov</addtitle><date>2019-04</date><risdate>2019</risdate><volume>9</volume><issue>4</issue><spage>469</spage><epage>471</epage><pages>469-471</pages><issn>2159-8274</issn><eissn>2159-8290</eissn><abstract>In this issue, Maertens and colleagues demonstrate that HDAC3 inhibition potentiates the effects of MAPK pathway inhibitors in melanoma, including difficult-to-treat - and -driven tumors, with expression serving as a biomarker for responsiveness to the BRAF/MEK/HDAC inhibitor combination. Mechanistically, this triple cocktail suppresses expression of genes involved in DNA repair, leading to enhanced killing of melanoma cells. .</abstract><cop>United States</cop><pmid>30936219</pmid><doi>10.1158/2159-8290.CD-19-0069</doi><tpages>3</tpages><orcidid>https://orcid.org/0000-0002-4292-0185</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2159-8274
ispartof Cancer discovery, 2019-04, Vol.9 (4), p.469-471
issn 2159-8274
2159-8290
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6446927
source MEDLINE; American Association for Cancer Research; EZB-FREE-00999 freely available EZB journals
subjects DNA Repair - drug effects
GTP Phosphohydrolases - genetics
Humans
Melanoma - genetics
Membrane Proteins - genetics
Protein Kinase Inhibitors
Proto-Oncogene Proteins B-raf - genetics
title Combined MAPK Pathway and HDAC Inhibition Breaks Melanoma
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-03T07%3A53%3A00IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Combined%20MAPK%20Pathway%20and%20HDAC%20Inhibition%20Breaks%20Melanoma&rft.jtitle=Cancer%20discovery&rft.au=Lombard,%20David%20B&rft.date=2019-04&rft.volume=9&rft.issue=4&rft.spage=469&rft.epage=471&rft.pages=469-471&rft.issn=2159-8274&rft.eissn=2159-8290&rft_id=info:doi/10.1158/2159-8290.CD-19-0069&rft_dat=%3Cproquest_pubme%3E2202196730%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2202196730&rft_id=info:pmid/30936219&rfr_iscdi=true